Pfizer to Buy Oncology Biotech Trillium in $2.26 Billion Deal
Pfizer has entered into a $2.26 billion purchase agreement with Canadian drugmaker Trillium Therapeutics in a move to expand its portfolio of cancer treatments.
The deal will give Pfizer access to Trillum’s two lead candidates, TTI-622 and TTI-621, developed to enhance the immune system’s ability to identify and destroy cancer cells.
The two molecules target the CD47 checkpoint found in hematological malignancies that shields some cancer cells from attack by the immune system. Hematological malignancies include cancers of the blood, bone marrow and lymph nodes, encompassing various forms of leukemia, multiple myeloma and lymphoma.
TTI-622 and TTI-621 are the only CD47-targeted molecules to show meaningful monotherapy activity and complete responses across multiple hematological malignancies, the companies said.